Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan-eluting beads
- Development stage
- Phase 2
- Lead developer
- Bio-Technology General
- Modality
- Small Molecules
- Administration
- Intra-arterial
01
Overview
Irinotecan-eluting beads (DEBIRI) are a drug delivery system consisting of microspheres loaded with irinotecan for targeted treatment of liver tumors. The beads are administered via transarterial chemoembolization (TACE), delivering irinotecan directly to tumor sites while simultaneously blocking blood flow to the tumor. This approach provides higher local drug concentration, reduced systemic toxicity, and prolonged drug release compared to conventional systemic chemotherapy.
- Brand names
- LifePearl
- Other names
- LifePearl Drug Elutable MicrospheresLifePearl MicrospheresLifePearls
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on irinotecan-eluting beads.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan-eluting beads.